Bria-PROS+ Clears IND Review for Prostate Cancer
The U.S. Food and Drug Administration issued a Study May Proceed letter for Bria-PROS+, allowing BriaCell Therapeutics to initiate a Phase 1/2a study in prostate cancer. Bria-PROS+ is a personalized, off-the-shelf, cell-based immunotherapy built…
